Odronextamab
R1979-ONC-2105
Phase 3 small_molecule active
Quick answer
Odronextamab for Diffuse Large B-cell Lymphoma (DLBCL) is a Phase 3 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- REGENERON PHARMACEUTICALS, INC.
- Indication
- Diffuse Large B-cell Lymphoma (DLBCL)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active